We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
- Authors
van Oosterom, A T; Judson, I; Verweij, J; Stroobants, S; Donato di Paola, E; Dimitrijevic, S; Martens, M; Webb, A; Sciot, R; Van Glabbeke, M; Silberman, S; Nielsen, O S; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
- Abstract
Gastrointestinal stromal tumours (GISTs) are rare tumours of the gastrointestinal tract characterised by cell-surface expression of the tyrosine kinase KIT (CD117). No effective systemic treatment is available. Imatinib (STI571) inhibits a similar tyrosine kinase, BCR-ABL, leading to responses in chronic myeloid leukaemia, and has also been shown to inhibit KIT. We did a phase I study to identify the dose-limiting toxic effects of imatinib in patients with advanced soft tissue sarcomas including GISTs.
- Publication
Lancet (London, England), 2001, Vol 358, Issue 9291, p1421
- ISSN
0140-6736
- Publication type
Journal Article
- DOI
10.1016/s0140-6736(01)06535-7